Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167855 | 1.00 | PTK6 (0.38) | PTK6KMT2AAURKBAURKAALDH1A1 | |
| SCHEMBL24105243 | 0.96 | PTK6 (0.40) | PTK6KMT2AAURKBAURKAALDH1A1 | |
| SCHEMBL30167771 | 0.96 | PTK6 (0.40) | PTK6KMT2AAURKBAURKAALDH1A1 | |
| SCHEMBL25170711 | 0.90 | KMT2A (0.38) | PTK6KMT2AAURKBAURKAALDH1A1 | |
| SCHEMBL30167773 | 0.90 | PTK6 (0.38) | PTK6KMT2AAURKBAURKAALDH1A1 | |
| SCHEMBL24105246 | 0.90 | PTK6 (0.38) | PTK6KMT2AAURKBAURKAALDH1A1 | |
| SCHEMBL30167729 | 0.88 | PTK6 (0.41) | PTK6KMT2AAURKBAURKAALDH1A1 | |
| SCHEMBL24105198 | 0.88 | PTK6 (0.41) | PTK6KMT2AAURKBAURKAALDH1A1 | |
| SCHEMBL25176778 | 0.88 | CCNT1 (0.36) | PTK6KMT2AAURKBAURKAALDH1A1 | |
| SCHEMBL25177003 | 0.88 | PTK6 (0.39) | PTK6AURKBAURKAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | claimed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021249893-A1 | NOVEL IMIDAZO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | PTK6 2213/4885KMT2A 3088/4885AURKB 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.